-
Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies
-
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.
Curi Bio and NEXEL Form Celogics, a Joint Venture to Develop iPSC-Derived Products
Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing.
OCTOBER 26, 2021, SEATTLE and SEOUL – Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA. [Read more…]
Bone Therapeutics Signs Research Partnership with Implant Therapeutics to Access iPSCs
-
Bone Therapeutics has partnered with Implant Therapeutics to gain access to iPSC derived, genetically engineered MSCs. These
-
Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise
Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies
-
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
-
Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies
ELK CITY, Idaho, Oct. 4, 2021 — Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced laboratory data demonstrating that exosomes produced by JadiCells™, the Company’s Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps. [Read more…]
Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with “Top 100 Innovation CEO” Award
September 21, 2021, Palo Alto, California – Koji Tanabe, Founder and CEO of I Peace, Inc., has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021”. [Read more…]
- « Previous Page
- 1
- …
- 86
- 87
- 88
- 89
- 90
- …
- 201
- Next Page »